688520 神州细胞
已收盘 03-23 15:00:00
资讯
新帖
简况
每周股票复盘：神州细胞（688520）拟募资9亿元补流
证券之星 · 03-22 02:23
每周股票复盘：神州细胞（688520）拟募资9亿元补流
神州细胞（688520）股东拉萨爱力克投资咨询有限公司质押3500万股，占总股本7.86%
证券之星 · 03-21
神州细胞（688520）股东拉萨爱力克投资咨询有限公司质押3500万股，占总股本7.86%
每周股票复盘：神州细胞（688520）2025年净亏5.53亿
证券之星 · 03-01
每周股票复盘：神州细胞（688520）2025年净亏5.53亿
神州细胞发布2025年度业绩快报，亏损5.533亿元
证券之星 · 02-27
神州细胞发布2025年度业绩快报，亏损5.533亿元
股市必读：神州细胞（688520）2月9日披露最新机构调研信息
证券之星 · 02-10
股市必读：神州细胞（688520）2月9日披露最新机构调研信息
股市必读：神州细胞（688520）预计2025年全年扣非后净利润亏损5.03亿元至5.63亿元
证券之星 · 02-02
股市必读：神州细胞（688520）预计2025年全年扣非后净利润亏损5.03亿元至5.63亿元
每周股票复盘：神州细胞（688520）预计2025年净亏损5.2亿至5.8亿元
证券之星 · 02-01
每周股票复盘：神州细胞（688520）预计2025年净亏损5.2亿至5.8亿元
神州细胞（688520）披露2025年年度业绩预告，1月30日股价下跌3.24%
证券之星 · 01-30
神州细胞（688520）披露2025年年度业绩预告，1月30日股价下跌3.24%
每周股票复盘：神州细胞（688520）定增获证监会注册批复
证券之星 · 01-11
每周股票复盘：神州细胞（688520）定增获证监会注册批复
神州细胞最新公告：向特定对象发行股票注册申请获中国证监会同意批复
证券之星 · 01-05
神州细胞最新公告：向特定对象发行股票注册申请获中国证监会同意批复
每周股票复盘：神州细胞（688520）拟与控股股东共同增资子公司
证券之星 · 01-02
每周股票复盘：神州细胞（688520）拟与控股股东共同增资子公司
神州细胞（688520）披露股东会决议公告，12月30日股价下跌0.82%
证券之星 · 2025-12-30
神州细胞（688520）披露股东会决议公告，12月30日股价下跌0.82%
神州细胞向控股股东不超9亿定增获通过 中信证券建功
中金财经 · 2025-12-08
神州细胞向控股股东不超9亿定增获通过 中信证券建功
11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股
证券之星 · 2025-11-04
11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股
每周股票复盘：神州细胞（688520）股东户数增40.96%
证券之星 · 2025-11-02
每周股票复盘：神州细胞（688520）股东户数增40.96%
神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显
证券之星 · 2025-11-01
神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显
图解神州细胞三季报：第三季度单季净利润同比下降994.50%
证券之星 · 2025-10-30
图解神州细胞三季报：第三季度单季净利润同比下降994.50%
每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购
证券之星 · 2025-10-19
每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购
神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法
红星资本局 · 2025-10-15
神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法
股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
证券之星 · 2025-10-15
股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
加载更多
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":36.4,"timestamp":1774249200000,"preClose":38,"halted":0,"volume":2956523,"delay":0,"changeRate":-0.0421,"floatShares":445000000,"shares":445000000,"eps":-0.6483,"marketStatus":"已收盘","change":-1.6,"latestTime":"03-23 15:00:00","open":37.71,"high":38.22,"low":36.2,"amount":110000000,"amplitude":0.0532,"askPrice":36.6,"askSize":63,"bidPrice":36.4,"bidSize":183,"shortable":0,"etf":0,"ttmEps":-0.6483,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":38,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":41.8,"lowLimit":34.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":445335714,"isCdr":false,"pbRate":-22.39,"roa":"--","roe":"0.0%","epsLYR":0.24,"committee":0.239583,"marketValue":16210000000,"turnoverRate":0.0066,"status":1,"afterMarket":{"amount":0,"volume":0,"close":36.4,"buyVolume":0,"sellVolume":0,"time":1774251237558,"indexStatus":"已收盘 03-23 15:30:00","preClose":38},"floatMarketCap":16210000000},"requestUrl":"/m/hq/s/688520","defaultTab":"news","newsList":[{"id":"2621279620","title":"每周股票复盘：神州细胞（688520）拟募资9亿元补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2621279620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621279620?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:23","pubTimestamp":1774117389,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，神州细胞报收于38.0元，较上周的39.4元下跌3.55%。本周，神州细胞3月17日盘中最高价报41.56元。神州细胞当前最新总市值169.23亿元，在生物制品板块市值排名18/51，在两市A股市值排名1182/5190。本周关注点公司公告汇总：神州细胞拟向控股股东定向发行不超过2500万股，募资不超过9亿元用于补充流动资金。神州细胞控股股东拉萨爱力克持有公司股份271,212,760股，占总股本60.90%。本次质押未用于重大资产重组业绩补偿，不具有潜在业绩补偿义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2621753179","title":"神州细胞（688520）股东拉萨爱力克投资咨询有限公司质押3500万股，占总股本7.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621753179","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621753179?lang=zh_cn&edition=full","pubTime":"2026-03-21 00:17","pubTimestamp":1774023441,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞3月21日公开信息显示，股东拉萨爱力克投资咨询有限公司向中国工商银行股份有限公司北京经济技术开发区分行合计质押3500.0万股，占总股本7.86%。质押详情见下表：截止本公告日，股东拉萨爱力克投资咨询有限公司已累计质押股份3500.0万股，占其持股总数的12.9%。神州细胞主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2616084564","title":"每周股票复盘：神州细胞（688520）2025年净亏5.53亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616084564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616084564?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:47","pubTimestamp":1772304428,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，神州细胞报收于39.41元，较上周的39.38元上涨0.08%。本周，神州细胞2月25日盘中最高价报40.15元。本周关注点来自业绩披露要点：神州细胞2025年归属净利润亏损5.533亿元，同比减少594.23%。公司公告汇总北京神州细胞生物技术集团股份公司发布2025年度业绩快报。业绩下滑主要受医保控费政策影响，核心产品安佳因多次降价导致收入下降，同时销售费用上升及研发投入保持高位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2614835593","title":"神州细胞发布2025年度业绩快报，亏损5.533亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835593","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835593?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183832,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损5.533亿元，同比减少594.23%。神州细胞（688520）主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2610571816","title":"股市必读：神州细胞（688520）2月9日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2610571816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610571816?lang=zh_cn&edition=full","pubTime":"2026-02-10 00:40","pubTimestamp":1770655225,"startTime":"0","endTime":"0","summary":"截至2026年2月9日收盘，神州细胞报收于40.25元，上涨0.62%，换手率0.32%，成交量1.42万手，成交额5730.04万元。安佳因2025年销售下降主要受医保控费及自2025年第三季度起大幅降价影响；公司期待降价有助于提升患者用药可及性。公司已于2026年1月获定增注册批文，控股股东拟认购不超过9亿元股份，发行将择机启动。计划2026年推进多款新产品申报IND。调研过程中公司严格遵守信息披露制度，确保信息真实、准确、完整、及时、公平，未发生重大未公开信息泄露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000000808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2608881944","title":"股市必读：神州细胞（688520）预计2025年全年扣非后净利润亏损5.03亿元至5.63亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608881944","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608881944?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:34","pubTimestamp":1769978050,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，神州细胞报收于41.85元，下跌3.24%，换手率0.59%，成交量2.65万手，成交额1.12亿元。来自：神州细胞预计2025年年度归母净利润为-5.8亿元到-5.2亿元，与上年同期相比由盈转亏。业绩披露要点业绩预告神州细胞发布业绩预告，预计2025年全年扣非后净利润亏损5.03亿元至5.63亿元；预计2025年全年归属净利润亏损5.2亿元至5.8亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2608070824","title":"每周股票复盘：神州细胞（688520）预计2025年净亏损5.2亿至5.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070824","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070824?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:48","pubTimestamp":1769888889,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，神州细胞报收于41.85元，较上周的46.33元下跌9.67%。本周，神州细胞1月26日盘中最高价报46.83元。神州细胞当前最新总市值186.37亿元，在生物制品板块市值排名16/51，在两市A股市值排名1137/5184。业绩披露要点神州细胞发布业绩预告，预计2025年全年归属净利润亏损5.2亿元至5.8亿元。公司公告汇总北京神州细胞生物技术集团股份公司预计2025年年度实现归属于母公司所有者的净利润为-58,000.00万元到-52,000.00万元，与上年同期相比由盈转亏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2607042450","title":"神州细胞（688520）披露2025年年度业绩预告，1月30日股价下跌3.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042450","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042450?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:25","pubTimestamp":1769786714,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，神州细胞报收于41.85元，较前一交易日下跌3.24%，最新总市值为186.37亿元。该股当日开盘43.21元，最高43.77元，最低41.82元，成交额达1.12亿元，换手率为0.59%。近日，北京神州细胞生物技术集团股份公司披露2025年年度业绩预告。业绩变动主要原因包括核心产品销售收入下降、商业化投入增加及研发支出保持高位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2602224535","title":"每周股票复盘：神州细胞（688520）定增获证监会注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602224535","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602224535?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:22","pubTimestamp":1768072930,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，神州细胞报收于49.16元，较上周的43.31元上涨13.51%。本周，神州细胞1月9日盘中最高价报49.38元。1月5日盘中最低价报43.18元。神州细胞当前最新总市值218.93亿元，在生物制品板块市值排名14/51，在两市A股市值排名959/5182。本周关注点公司公告汇总：神州细胞2025年度向特定对象发行股票获中国证监会同意注册批复。批复自同意注册之日起12个月内有效。公司将在规定期限内办理发行相关事项，并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2601007227","title":"神州细胞最新公告：向特定对象发行股票注册申请获中国证监会同意批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007227","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007227?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:01","pubTimestamp":1767607273,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司于近日收到中国证券监督管理委员会出具的《关于同意北京神州细胞生物技术集团股份公司向特定对象发行股票注册的批复》，同意公司向特定对象发行股票的注册申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2600036903","title":"每周股票复盘：神州细胞（688520）拟与控股股东共同增资子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036903?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:03","pubTimestamp":1767294191,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，神州细胞报收于44.22元，较上周的44.57元下跌0.79%。本周关注点公司公告汇总：神州细胞拟与控股股东共同向控股子公司神州细胞工程有限公司增资暨关联交易。本次股东会审议通过了聘请2025年度审计机构、2026年度对外捐赠额度、修订多项公司制度及与控股股东共同向控股子公司增资暨关联交易等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2595934795","title":"神州细胞（688520）披露股东会决议公告，12月30日股价下跌0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595934795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595934795?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:58","pubTimestamp":1767088726,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，神州细胞报收于43.59元，较前一交易日下跌0.82%，最新总市值为194.12亿元。近日，神州细胞发布2025年第二次临时股东会决议公告，宣布公司于2025年12月29日召开2025年第二次临时股东会，审议通过了关于聘请2025年度审计机构、2026年度对外捐赠额度、修订多项公司制度及与控股股东共同向控股子公司神州细胞工程有限公司增资暨关联交易的议案。涉及关联交易的议案已获出席股东所持表决权三分之二以上通过，关联股东已回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2589828643","title":"神州细胞向控股股东不超9亿定增获通过 中信证券建功","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828643","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589828643?lang=zh_cn&edition=full","pubTime":"2025-12-08 14:53","pubTimestamp":1765176795,"startTime":"0","endTime":"0","summary":"神州细胞日前发布《关于2025年度向特定对象发行A股股票申请收到上海证券交易所审核意见通知的公告》。 神州细胞表示，公司本次向特定对象发行A股股票事项尚需获得中国证监会作出同意注册的决定后方可实施，最终能否获得中国证监会同意注册的决定及其时间尚存在不确定性。 神州细胞本次发行的保荐机构为中信证券股份有限公司，保荐代表人为丁元、黄可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251208/31850349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0405327148.USD","688520","BK0183","LU1997244956.HKD","LU2495084118.USD","LU1655091616.SGD","LU1720050803.USD","BK1564","BK0188","BK0196","LU1997245177.USD","LU2289578879.USD","BK0239","LU1064130708.USD","BK1521","BK0276","LU2148510915.USD","BK0028","BK1147","BK1516","06030","BK0012","LU1794554557.SGD","LU1064131003.USD","LU1997245094.SGD","LU0405327494.USD","LU1328615791.USD","LU1255011170.USD","600030"],"gpt_icon":0},{"id":"2580788522","title":"11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788522?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:29","pubTimestamp":1762244992,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日神州细胞跌5.55%，收盘报51.25元，换手率1.42%，成交量6.3万手，成交额3.26亿元。重仓神州细胞的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为前海开源基金的前海开源再融资股票。前海开源再融资股票目前规模为4.84亿元，最新净值1.428，较上一交易日下跌0.07%，近一年上涨21.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["162717","BK0239","688520"],"gpt_icon":0},{"id":"2580472831","title":"每周股票复盘：神州细胞（688520）股东户数增40.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472831","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472831?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:21","pubTimestamp":1762035670,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，神州细胞报收于53.7元，较上周的51.99元上涨3.29%。本周，神州细胞10月31日盘中最高价报54.0元。股本股东变化股东户数变动截至2025年9月30日，神州细胞股东户数为1.37万户，较6月30日增加3995.0户，增幅40.96%。业绩披露要点财务报告神州细胞2025年三季报显示，前三季度主营收入13.12亿元，同比下降32.27%；归母净利润-2.51亿元，同比下降267.17%；扣非净利润-2.0亿元，同比下降143.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2580640417","title":"神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2580640417","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580640417?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:52","pubTimestamp":1761951130,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2025年三季报。截至本报告期末，公司营业总收入13.12亿元，同比下降32.27%，归母净利润-2.51亿元，同比下降267.17%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达72.53%。去年的净利率为4.47%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2579092144","title":"图解神州细胞三季报：第三季度单季净利润同比下降994.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579092144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579092144?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:54","pubTimestamp":1761828895,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2025年三季报显示，前三季度公司主营收入13.12亿元，同比下降32.27%；归母净利润-2.51亿元，同比下降267.17%；扣非净利润-2.0亿元，同比下降143.32%；其中2025年第三季度，公司单季度主营收入3.4亿元，同比下降46.25%；单季度归母净利润-2.17亿元，同比下降994.5%；单季度扣非净利润-1.64亿元，同比下降234.46%；负债率101.46%，投资收益73.43万元，财务费用6848.48万元，毛利率94.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2576041271","title":"每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041271","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041271?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:39","pubTimestamp":1760819948,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，神州细胞报收于52.89元，较上周的54.59元下跌3.11%。本周，神州细胞10月16日盘中最高价报56.3元。本周关注点公司公告汇总：神州细胞拟向控股股东拉萨爱力克发行不超过2500万股，募资不超9亿元用于补充流动资金，发行价36.00元/股。公司公告汇总神州细胞拟向特定对象发行A股股票，募集资金总额不超过90,000.00万元，扣除发行费用后全部用于补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2575122736","title":"神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法","url":"https://stock-news.laohu8.com/highlight/detail?id=2575122736","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575122736?lang=zh_cn&edition=full","pubTime":"2025-10-15 22:33","pubTimestamp":1760538780,"startTime":"0","endTime":"0","summary":" 红星资本局注意到，近年来神州细胞通过为患者提供补贴来扩大产品销量。10月15日，神州细胞证券部回应红星资本局称，对患者进行大额补贴是行业的普遍做法，有利于公司推广产品。红星资本局发现，销售费用和营业外支出均与公司通过给予患者补贴扩大销售有关。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-15/doc-inftywai7940558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2575446342","title":"股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2575446342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575446342?lang=zh_cn&edition=full","pubTime":"2025-10-15 03:47","pubTimestamp":1760471228,"startTime":"0","endTime":"0","summary":"公司公告汇总北京神州细胞生物技术集团股份公司拟向特定对象发行A股股票，募集资金总额不超过90,000.00万元，用于补充流动资金。公司已履行相关决策程序，发行定价符合规定，不存在损害中小股东利益的情形。公司于2025年9月5日收到上交所出具的审核问询函，已会同中介机构完成回复，并更新2025年半年度财务报告相关内容。本次发行尚需通过上交所审核并获中国证监会注册，最终能否获批及时间存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500003572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774302949176,"stockEarnings":[{"period":"1week","weight":-0.1057},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.167},{"period":"6month","weight":-0.3596},{"period":"1year","weight":-0.0606},{"period":"ytd","weight":-0.1595}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13749人(较上一季度增加40.96%)","perCapita":"32390股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"44533万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}